Corcept Therapeutics IncCORT
ASignal's systematic analysis rates CORT as Bullish.
Reflects the latest available analysis · analyzed Aug 23, 2026
The case on CORT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (31.7% YoY)
- High gross margin (98.3%) indicating pricing power
- Low debt-to-equity ratio (0.01x) signaling strong financial health
- Positive free cash flow ($77.4M)
- MACD above signal line with expanding histogram, confirming uptrend
- Price above SMA20 and SMA50, indicating bullish momentum
- High P/E ratio (271.67x) relative to earnings
- Elevated EV/EBITDA (1597.76x) suggesting valuation risk
- Low return on assets (0.47%)
- No Reddit mentions, indicating limited retail investor interest or sentiment data
See the full verdict on CORT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CORT
Most investors never get a second opinion, let alone several. ASignal runs CORT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.